Mark Pullen

1.5k total citations
43 papers, 1.0k citations indexed

About

Mark Pullen is a scholar working on Physiology, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Mark Pullen has authored 43 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Physiology, 15 papers in Molecular Biology and 14 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Mark Pullen's work include Nitric Oxide and Endothelin Effects (17 papers), Renin-Angiotensin System Studies (11 papers) and Receptor Mechanisms and Signaling (9 papers). Mark Pullen is often cited by papers focused on Nitric Oxide and Endothelin Effects (17 papers), Renin-Angiotensin System Studies (11 papers) and Receptor Mechanisms and Signaling (9 papers). Mark Pullen collaborates with scholars based in United States, United Kingdom and Netherlands. Mark Pullen's co-authors include Ponnal Nambi, David P. Brooks, Richard M. Edwards, Miklos Gellai, Lisa C. Contino, Eliot H. Ohlstein, P Nambi, Nambi Aiyar, Timothy D. Westfall and Robin DeWolf and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Immunology and Journal of Applied Physiology.

In The Last Decade

Mark Pullen

43 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Pullen United States	20	458	377	293	220	94	43	1.0k
Mohammed Yaqoob United Kingdom	18	329 0.7×	462 1.2×	156 0.5×	138 0.6×	96 1.0×	36	1.4k
Heiner Apeler Germany	11	649 1.4×	555 1.5×	332 1.1×	68 0.3×	56 0.6×	18	1.2k
Anthony C. Sulpizio United States	22	343 0.7×	750 2.0×	375 1.3×	411 1.9×	54 0.6×	35	1.7k
Zaichuan Mi United States	24	217 0.5×	666 1.8×	296 1.0×	286 1.3×	72 0.8×	72	1.8k
D L Saussy United States	14	325 0.7×	446 1.2×	114 0.4×	217 1.0×	31 0.3×	18	806
Jennifer L. Busch United States	5	330 0.7×	421 1.1×	173 0.6×	78 0.4×	44 0.5×	9	864
Pavel I. Nedvetsky Germany	18	558 1.2×	895 2.4×	236 0.8×	155 0.7×	55 0.6×	39	1.5k
Eva Maria Becker Germany	7	348 0.8×	335 0.9×	327 1.1×	58 0.3×	37 0.4×	11	720
Angela Wirth Germany	15	327 0.7×	856 2.3×	285 1.0×	121 0.6×	40 0.4×	26	1.4k
Ivan Milicic United States	19	202 0.4×	554 1.5×	164 0.6×	151 0.7×	48 0.5×	42	1.1k

Countries citing papers authored by Mark Pullen

Since Specialization

Citations

This map shows the geographic impact of Mark Pullen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Pullen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Pullen more than expected).

Fields of papers citing papers by Mark Pullen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Pullen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Pullen. The network helps show where Mark Pullen may publish in the future.

Co-authorship network of co-authors of Mark Pullen

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Pullen. A scholar is included among the top collaborators of Mark Pullen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Pullen. Mark Pullen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Borthwick, Alan D., John Liddle, Anne M. Exall, et al.. (2012). Pyridyl-2,5-Diketopiperazines as Potent, Selective, and Orally Bioavailable Oxytocin Antagonists: Synthesis, Pharmacokinetics, and In Vivo Potency. Journal of Medicinal Chemistry. 55(2). 783–796. 54 indexed citations

Hilfiker, Mark A., Ning Wang, Zhimin Du, et al.. (2009). Discovery of novel aminothiadiazole amides as selective EP3 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 19(15). 4292–4295. 15 indexed citations

Hicks, Alexandra, Gerald P. McCafferty, Nambi Aiyar, et al.. (2007). GW427353 (Solabegron), a Novel, Selective β3-Adrenergic Receptor Agonist, Evokes Bladder Relaxation and Increases Micturition Reflex Threshold in the Dog. Journal of Pharmacology and Experimental Therapeutics. 323(1). 202–209. 70 indexed citations

Ramírez-Molina, César, Olivier Heudi, Mark Pullen, & Peter S. Marshall. (2005). Study of bradykinin metabolism by rat lung tissue membranes and rat kidney brush border membranes by HPLC with inductively coupled plasma—mass spectrometry and orthogonal acceleration time-of-flight mass spectrometry. Journal of Peptide Science. 12(3). 220–226. 11 indexed citations

Johnson, Eric N., Edward R. Appelbaum, Richard F. Cox, et al.. (2004). Neuromedin Elicits Cytokine Release in Murine Th2-Type T Cell Clone D10.G4.1. The Journal of Immunology. 173(12). 7230–7238. 43 indexed citations

Sulpizio, Anthony C., Mark Pullen, Richard M. Edwards, & David P. Brooks. (2004). The Effect of Acute Angiotensin-Converting Enzyme and Neutral Endopeptidase 24.11 Inhibition on Plasma Extravasation in the Rat. Journal of Pharmacology and Experimental Therapeutics. 309(3). 1141–1147. 32 indexed citations

Westfall, Timothy D., Gerald P. McCafferty, Mark Pullen, et al.. (2003). Effect of Endothelin on Bladder Contraction: Potential Role in Bladder Hyperactivity. Pharmacology. 69(1). 7–11. 12 indexed citations

Barone, Frank C., Wallace G. Campbell, Allen H. Nelson, et al.. (2002). The Angiotensin Type 1 Receptor Antagonist, Eprosartan, Attenuates the Progression of Renal Disease in Spontaneously Hypertensive Stroke-Prone Rats with Accelerated Hypertension. Journal of Pharmacology and Experimental Therapeutics. 301(1). 21–28. 15 indexed citations

Westfall, Timothy D., Gerald P. McCafferty, Mark Pullen, et al.. (2002). Characterization of Neuromedin U Effects in Canine Smooth Muscle. Journal of Pharmacology and Experimental Therapeutics. 301(3). 987–992. 38 indexed citations

10.

Pullen, Mark, et al.. (2001). Stimulation of Hyaluronan Synthetase by Platelet-Derived Growth Factor bb in Human Prostate Smooth Muscle Cells. Pharmacology. 62(2). 103–106. 8 indexed citations

11.

Louden, Calvert, Ponnal Nambi, Mark Pullen, et al.. (2000). Endothelin Receptor Subtype Distribution Predisposes Coronary Arteries to Damage. American Journal Of Pathology. 157(1). 123–134. 19 indexed citations

12.

Griswold, Don E., Lenox D. Martin, Laura Davis, et al.. (1999). Endothelin B Receptor Modulates Inflammatory Pain and Cutaneous Inflammation. Molecular Pharmacology. 56(4). 807–812. 68 indexed citations

13.

Brooks, David P., et al.. (1998). SB 234551, a Novel Endothelin-A Receptor Antagonist, Unmasks Endothelin-Induced Renal Vasodilatation in the Dog. Journal of Cardiovascular Pharmacology. 31. S339–S341. 13 indexed citations

14.

Willette, Robert N., Julie A. Ellison, Brian Short, et al.. (1998). Effects of Endothelin Receptor Antagonism and Angiotensin-Converting Enzyme Inhibition on Cardiac and Renal Remodeling in the Rat. Journal of Cardiovascular Pharmacology. 31. S277–S283. 4 indexed citations

15.

Louden, Calvert, Ponnal Nambi, C A Branch, et al.. (1998). Coronary Arterial Lesions in Dogs Treated With an Endothelin Receptor Antagonist. Journal of Cardiovascular Pharmacology. 31. S384–S385. 11 indexed citations

16.

Elshourbagy, Nabil A., John E. Adamou, Alison W. Gagnon, et al.. (1996). Molecular Characterization of a Novel Human Endothelin Receptor Splice Variant. Journal of Biological Chemistry. 271(41). 25300–25307. 51 indexed citations

17.

Brooks, David P., et al.. (1995). Identification and Function of Putative ETB Receptor Subtypes in the Dog Kidney. Journal of Cardiovascular Pharmacology. 26. S322–325. 22 indexed citations

18.

Pullen, Mark, et al.. (1994). Characterization of a Functional Angiotensin II Receptor in <i>Xenopus laevis </i>Heart. Pharmacology. 48(4). 242–249. 8 indexed citations

19.

Gellai, Miklos, Robin DeWolf, Mark Pullen, & P Nambi. (1994). Distribution and functional role of renal ET receptor subtypes in normotensive and hypertensive rats. Kidney International. 46(5). 1287–1294. 66 indexed citations

20.

Brooks, David P., Eliot H. Ohlstein, Barbara L. Storer, et al.. (1991). Effect of nifedipine on cyclosporine A-induced nephrotoxicity, urinary endothelin excretion and renal endothelin receptor number. European Journal of Pharmacology. 194(1). 115–117. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact